Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Long-term Safety in Systemic Lupus Erythematosus
CTR20200424Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of baricitinib in systemic lupus erythematosus (SLE), sponsored by Eli Lilly and Company. Started May 2020; status: terminated.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20200424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200424.